Abbvie Inc (NYSE:ABBV) shares traded 1.32% higher at $153.24 on Wall Street last session.
In accordance with the data, 28 analysts cover Abbvie Inc (NYSE:ABBV). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $205.00 and a low of $135.00, we find $170.00. Given the previous closing price of $151.24, this indicates a potential upside of 12.4 percent. ABBV stock price is now 6.67% away from the 50-day moving average and 4.27% away from the 200-day moving average. The market capitalization of the company currently stands at $270.55B.
It has been rated a hold by 13 analysts and a buy by 12. Brokers who have rated the stock have averaged $170.51 as their price target over the next twelve months.
In other news, GONZALEZ RICHARD A, CHAIRMAN OF THE BOARD AND CEO sold 60,000 shares of the company’s stock on Aug 01. The stock was sold for $8,914,800 at an average price of $148.58. Upon completion of the transaction, the CHAIRMAN OF THE BOARD AND CEO now directly owns 565,294 shares in the company, valued at $86.63 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 31, CHAIRMAN OF THE BOARD AND CEO GONZALEZ RICHARD A sold 18,500 shares of the business’s stock. A total of $2,759,275 was realized by selling the stock at an average price of $149.15. This leaves the insider owning 625,294 shares of the company worth $95.82 million. Insiders disposed of 771,700 shares of company stock worth roughly $118.26 million over the past 1 year. A total of 0.14% of the company’s stock is owned by insiders.
Abbvie Inc (NYSE: ABBV) opened at $151.73 on Tuesday. During the past 12 months, Abbvie Inc has had a low of $130.96 and a high of $168.11. As of last week, the company has a debt-to-equity ratio of 5.02, a current ratio of 0.96, and a quick ratio of 0.84. The fifty day moving average price for ABBV is $143.66 and a two-hundred day moving average price translates $146.96 for the stock.
The latest earnings results from Abbvie Inc (NYSE: ABBV) was released for Sep, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $2.95, beating analysts’ expectations of $2.86 by 0.09. This compares to $2.23 EPS in the same period last year. The net profit margin was 11.75% and return on equity was 46.15% for ABBV. The company reported revenue of $13.93 billion for the quarter, compared to $14.81 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -5.97 percent. For the current quarter, analysts expect ABBV to generate $13.96B in revenue.
Abbvie Inc(ABBV) Company Profile
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet’s diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson’s disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; California Institute for Biomedical Research (Calibr), and BigHat Biosciences, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
